CYAD News and Press, Celyad SA

MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced...

2023-04-24 16:30:50 ET Celyad Oncology ( NASDAQ: CYAD ) received a letter on April 19th from the Nasdaq informing that the company's minimum closing bid price per share was below $1 for a period of 30 consecutive days and did not meet the minimum bid price requirement. Th...

MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Bid Price No...

2023-04-04 16:21:30 ET Celyad Oncology ( NASDAQ: CYAD ) said on Tuesday that the biotechnology company received a Nasdaq notice over failure to maintain continued listing requirements under the stock exchange's rules. The stock exchange requires a listed company to maintain&#x...

MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letterȁ...

2023-03-24 10:39:02 ET Celyad Oncology SA (CYAD) Q4 2022 Results Earnings Conference Call March 24, 2023, 08:00 AM ET Company Participants David Georges - Vice President of Finance and Administration Michel Lussier - Interim Chief Executive Officer Eytan Breman -...

2023-03-24 05:40:01 ET Celyad Oncology ( NASDAQ: CYAD ) appointed Georges Rawadi as CEO, effective March 23, but would start on April 17. Michel Lussier will continue to serve as interim CEO until April 17 to help with the transition, according to the company. Rawadi h...

MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased to announce Georges Rawadi as it...

2023-03-23 17:07:40 ET Celyad Oncology press release ( NASDAQ: CYAD ): FY GAAP EPS of -€1.81. As of December 31, 2022, the Company had cash and cash equivalents of €12.4 million ($13.3 million). The Company projects that its existing cash and cash equival...

Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via (i) strengthening of its research focus centered around NKG2D, B7-H6 and shRNA platforms; (ii) max...